AI Article Synopsis
- The RE-MIND2 study compared patient outcomes of tafasitamab plus lenalidomide to other systemic therapies for relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
- Data from eligible patients aged 18 and older who had previously received multiple treatments were analyzed, and matching was done to ensure comparable groups for accurate results.
- The findings indicated that patients receiving tafasitamab plus lenalidomide experienced significantly improved overall survival compared to those on pooled systemic therapies, bendamustine plus rituximab, and rituximab plus gemcitabine and oxaliplatin.
Article Abstract
Purpose: In RE-MIND2 (NCT04697160), patient-level outcomes from the L-MIND study (NCT02399085) of tafasitamab plus lenalidomide were retrospectively compared with patient-level matched observational cohorts treated with National Cancer Care Network (NCCN)/European Society for Medical Oncology (ESMO)-listed systemic therapies for relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
Patients And Methods: Data were collected from health records of eligible patients aged ≥18 years with histologically confirmed DLBCL who had received ≥2 systemic therapies for DLBCL (including ≥1 anti-CD20 therapy). Patients from L-MIND were matched with patients from the RE-MIND2 observational cohort using estimated propensity score-based 1:1 nearest-neighbor matching, balanced for nine covariates. The primary analysis compared tafasitamab plus lenalidomide with patients who received any systemic therapy for R/R DLBCL (pooled in one cohort) or bendamustine plus rituximab (BR) or rituximab plus gemcitabine and oxaliplatin (R-GemOx; as two distinct cohorts). The primary endpoint was overall survival (OS). Secondary endpoints included treatment response and time-to-event outcomes.
Results: In RE-MIND2, 3,454 patients were enrolled from 200 sites in North America, Europe, and Asia-Pacific. Strictly matched pairs of patients consisted of tafasitamab plus lenalidomide versus systemic therapies pooled (n = 76 pairs), versus BR (n = 75 pairs), and versus R-GemOx (n = 74 pairs). Significantly prolonged OS was reported with tafasitamab plus lenalidomide versus systemic pooled therapies [hazard ratios (HR): 0.55; P = 0.0068], BR (HR: 0.42; P < 0.0001), and R-GemOx (HR: 0.47; P = 0.0003).
Conclusions: RE-MIND2, a retrospective observational study, met its primary endpoint, demonstrating prolonged OS with tafasitamab plus lenalidomide versus BR and R-GemOx. See related commentary by Cherng and Westin, p. 3908.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9475241 | PMC |
| http://dx.doi.org/10.1158/1078-0432.CCR-21-3648 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
SOHO State of the Art Updates and Next Questions | Diffuse Large B-Cell Lymphoma in Older Adults: A Comprehensive Review.
Clin Lymphoma Myeloma Leuk
November 2024
Memorial Sloan Kettering Cancer Center, New York City, NY. Electronic address:
Article Synopsis
- Older adults with diffuse large B-cell lymphoma (DLBCL) face unique challenges and poorer outcomes, highlighting the need for tailored care strategies.
- Geriatric assessment (GA) tools, like simplified GA (sGA), help categorize patients into fit, unfit, and frail groups to guide treatment decisions, including dose adjustments for chemotherapy.
- New treatment options, including CAR-T cell therapy and bispecific antibodies, are evolving to better serve older adults, particularly those who are unable to tolerate traditional therapies or who experience relapse after initial treatment.
How I Treat Older Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma.
Blood
October 2024
University of Rochester Medical Center, Rochester, New York, United States.
Article Synopsis
- * New treatment options are emerging; however, determining which are safe and effective for older patients, especially in cases of relapse, remains complicated and requires careful assessments.
- * The article outlines strategies for managing older adults with relapsed DLBCL, including advanced therapies like CAR-T cell therapy and other innovative treatments tailored for this age group.
Outcome of patients with large B-cell lymphoma treated with tafasitamab plus lenalidomide either before or after CAR T-cell therapy.
Blood Adv
October 2024
Department of Hematology, Centre Henri Becquerel, Rouen, France.
Tafasitamab plus lenalidomide (TAFA-LEN) treatment relevance pre- or post-anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is debated. We analyzed patients with large B-cell lymphoma in the DESCAR-T registry treated with axi[1]cel or tisa-cel in ≥3rd line and TAFA-LEN before (n = 15, "TL-pre-CAR-T" set) or directly after (n = 52, "TL-post-CAR-T" set) CAR T-cell therapy. We compared TAFA-LEN v.
View Article and Find Full Text PDFBlockade of the CD47/SIRPα checkpoint axis potentiates the macrophage-mediated antitumor efficacy of tafasitamab.
Haematologica
December 2024
Department of Internal Medicine 5, Hematology and Oncology, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen.
Article Synopsis
- Macrophages play a crucial role in the effectiveness of the anti-CD19 antibody tafasitamab, which is used to treat certain types of lymphoma.
- The study focuses on the CD47-SIRPα interaction, which can inhibit the macrophages' ability to effectively eliminate tumor cells, and suggests that blocking CD47 may boost tafasitamab's effectiveness.
- Experimental results showed that combining tafasitamab with an anti-CD47 antibody improved phagocytosis of lymphoma cells and resulted in better outcomes in animal models, indicating potential for clinical application.
Time-dependent cost comparison and health economic impact analysis of second-line interventions for transplant-ineligible patients with relapsed or refractory diffuse large B cell lymphoma.
Eur J Haematol
September 2024
VITIS Healthcare Group, Cologne, Germany.
Objectives: Novel interventions (axicabtagene ciloleucel [axi-cel], lisocabtagene maraleucel [liso-cel], tafasitamab-lenalidomide [Tafa-L], polatuzumab-rituximab-bendamustine [pola-BR]) improve clinical outcomes in second-line (2 L) treatment of transplant-ineligible patients with early relapse or refractory (R/R) diffuse large B cell lymphoma (DLBCL). The costs vary depending on the respective treatment regimen and the treatment duration, difficult comparability in reimbursement decisions. The objective was to analyze the health economic impacts of novel 2 L interventions and conventional immunochemotherapies (bendamustine-rituximab [BR], rituximab-gemcitabine-oxaliplatin [R-GemOx]) from a German healthcare payer's perspective as a function of treatment duration.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!